Alcon Agrees to Acquire STAAR Surgical, Deal Estimated at $1.5 Billion

Published on August 5, 2025
GENEVA and LAKE FOREST, Calif.—Global eyecare company Alcon (SIX/NYSE: ALC) and STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, announced this morning that the companies have entered into a definitive merger agreement in which Alcon intends to acquire STAAR. The transaction represents a total equity value of approximately $1.5 billion, and the acquisition includes the EVO ICL family of lenses for vision correction, the announcement stated.
Continue reading on website
Other news

Exploratory analysis discovers key predictive factors of improved BCVA in treatment of LHON disease with lenadogene nolparvovec

August 5, 2025
Better best-corrected visual acuity values and baseline thicker ganglion cell layer and retinal nerve fiber layer at ocular coherence tomography measurements were found to be the key predictive factors.

Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings

August 5, 2025
Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.